These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22335531)

  • 1. Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma.
    Rydström K; Joost P; Ehinger M; Edén P; Jerkeman M; Cavallin-Ståhl E; Linderoth J
    Leuk Lymphoma; 2012 Sep; 53(9):1764-8. PubMed ID: 22335531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Rydström K; Linderoth J; Nyman H; Ehinger M; Joost P; Bendahl PO; Leppä S; Jerkeman M
    Leuk Lymphoma; 2010 Sep; 51(9):1643-8. PubMed ID: 20593977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.
    Linderoth J; Jerkeman M; Cavallin-Ståhl E; Kvaløy S; Torlakovic E;
    Clin Cancer Res; 2003 Feb; 9(2):722-8. PubMed ID: 12576441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma.
    Linderoth J; Ehinger M; Jerkeman M; Bendahl PO; Akerman M; Berglund M; Enblad G; Erlanson M; Roos G; Cavallin-Ståhl E
    Leuk Lymphoma; 2007 Sep; 48(9):1774-9. PubMed ID: 17786713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
    Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
    Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Keeping good and bad company: stromal cells in lymphoma.
    Delabie J
    Leuk Lymphoma; 2012 Sep; 53(9):1654-5. PubMed ID: 22680767
    [No Abstract]   [Full Text] [Related]  

  • 7. CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8(+) T cell frequency and patient survival.
    Weiss JM; Gregory Alvord W; Quiñones OA; Stauffer JK; Wiltrout RH
    Hum Immunol; 2014 Jul; 75(7):614-20. PubMed ID: 24801648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vav-1 expression correlates with NFκB activation and CD40-mediated cell death in diffuse large B-cell lymphoma cell lines.
    Hollmann A; Aloyz R; Baker K; Dirnhofer S; Owens T; Sladek R; Tzankov A
    Hematol Oncol; 2010 Sep; 28(3):142-50. PubMed ID: 20155735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma.
    Linderoth J; Edén P; Ehinger M; Valcich J; Jerkeman M; Bendahl PO; Berglund M; Enblad G; Erlanson M; Roos G; Cavallin-Ståhl E
    Br J Haematol; 2008 May; 141(4):423-32. PubMed ID: 18419622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
    Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
    Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stromal immune infiltration in HIV-related diffuse large B-cell lymphoma is associated with HIV disease history and patient survival.
    Chao C; Xu L; Silverberg MJ; Martínez-Maza O; Chen LH; Castor B; Abrams DI; Zha HD; Haque R; Said J
    AIDS; 2015 Sep; 29(15):1943-51. PubMed ID: 26355571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.
    Wang WG; Jiang XN; Liu ZB; Zhou XY; Li XQ
    Am J Surg Pathol; 2017 Apr; 41(4):541-549. PubMed ID: 28291124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
    Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
    Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.
    Schuhmacher B; Rengstl B; Döring C; Bein J; Newrzela S; Brunnberg U; Kvasnicka HM; Vornanen M; Küppers R; Hansmann ML; Hartmann S
    Oncotarget; 2016 Nov; 7(44):72197-72210. PubMed ID: 27708232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic markers in diffuse large B-cell lymphoma.
    Delabie J
    Leuk Lymphoma; 2010 Sep; 51(9):1588-9. PubMed ID: 20807090
    [No Abstract]   [Full Text] [Related]  

  • 16. [Expression and clinical significance of CD40 in diffuse large B-cell lymphoma].
    Wang S; Wang YP; Hao YY; Zheng Y
    Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):819-23. PubMed ID: 24507100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
    Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
    Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel risk stratification of de novo diffuse large B cell lymphoma based on tumour-infiltrating T lymphocytes evaluated by flow cytometry.
    Chen Z; Deng X; Ye Y; Gao L; Zhang W; Liu W; Zhao S
    Ann Hematol; 2019 Feb; 98(2):391-399. PubMed ID: 30377764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma.
    Saez AI; García-Cosío M; Sáez AJ; Hernández JM; Sánchez-Verde L; Alvarez D; de la Cueva P; Arranz R; Conde E; Grande C; Rodríguez J; Caballero D; Piris MA
    Leuk Lymphoma; 2009 Apr; 50(4):571-81. PubMed ID: 19373655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.